Trial Profile

NAUTILUS: a Phase 1b/2 Study of OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors and Activating Mutations in the RAS Pathway (Phase 1b) and in Patients with Advanced NRAS-Mutated Melanoma (Phase 2)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Binimetinib (Primary) ; Bocodepsin (Primary)
Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms Nautilus
Sponsors OnKure Therapeutics

07 Mar 2025 Status changed from active, no longer recruiting to completed.
05 Mar 2024 Status changed from recruiting to active, no longer recruiting.
06 Dec 2022 According to an OnKure Therapeutics media release, the company plans to initiate the Phase 2 portion of this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com